ERBB2 and breast cancer: Evidence from clinical trials has shown that IMMU has beneficial effects, leading to its FDA approval for the treatment of unresectable locally advanced or metastatic TNBC, unresectable locally advanced or metastatic HR-positive/HER2-negative BC, and locally advanced or metastatic UC.